Advertisement


Alan Pollack, MD, PhD, on Prostate Cancer: Postprostatectomy Radiotherapy

2016 ASTRO Annual Meeting

Advertisement

Alan Pollack, MD, PhD, of the University of Miami Health System, summarizes a session that included discussion of outcomes, dose response, oligometastatic disease, and gene predictor of response. (Presentations 228-235)



Related Videos

Prostate Cancer

Anders Widmark, MD, PhD, on Intermediate-Risk Prostate Cancer: Results From the HYPO-RT-PC Trial

Anders Widmark, MD, PhD, of the Umea University Hospital Oncology, discusses the early toxicity results from the phase III Scandinavian study on extreme hypofractionation vs conventio...

Issues in Oncology

Howard M. Sandler, MD, on RTOG’s Past and NRG’s Future

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses prospective clinical trials as the gold standard of clinical decision-making and examines the infrastructure needed fo...

Prostate Cancer

Bradley R. Prestidge, MD, on Prostate Cancer: Initial Findings of NRG Oncology/RTOG 0232

Bradley R. Prestidge, MD, of Bon Secours VA Health System, summarizes his plenary lecture on this phase III trial comparing combined external beam radiation and transperineal intersti...

Bruce D. Minsky, MD's, Meeting Highlights: An Expert Perspective

Bruce D. Minsky, MD, of The University of Texas MD Anderson Cancer Center and Chairman of the ASTRO Board, discusses top papers presented at this year’s Annual Meeting.

Prostate Cancer

Daniel Hamstra, MD, PhD, on Prostate Cancer: Decreasing Rectal Toxicity

Daniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality ...

Advertisement

Advertisement



Advertisement